GlassScriptPhysician profile
David R Hulbert
NPI 1730313586
$2,173.66
in general payments reported to CMS, 2019-2025
33 companies · $878 in 2025
The $878 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $51.53 · 2023: $109 · 2024: $859 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,844.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $421.49 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $310.59 | 2019-2025 | |
| Dexcom, INC. | $257.73 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $121.75 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Tandem Diabetes Care, INC. | $102.09 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $93.50 | 2024-2025 | Evenity, Repatha, Prolia |
| Novartis Pharmaceuticals Corporation | $78.12 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $73.74 | 2024-2025 | Farxiga, Airsupra |
| Edwards Lifesciences Corporation | $66.38 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Bayer Healthcare Pharmaceuticals INC. | $56.19 | 2024 | |
| Medtronic, INC. | $50.12 | 2024-2025 | Minimed 780g, Inceptiv |
| Lilly USA, LLC | $49.80 | 2019-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $48.50 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.59 | 2019 | |
| Janssen Pharmaceuticals, INC | $37.24 | 2024-2025 | Spravato |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $35.73 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $32.95 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $29.98 | 2024 | Daybue |
| Exact Sciences Corporation | $28.60 | 2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $24.45 | 2025 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $22.77 | 2024 | Rexulti |
| Shield Therapeutics INC | $21.92 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.91 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.63 | 2025 | Recorlev |
| Philips North America LLC | $17.69 | 2024 | (Ck4) Mcot |
| Dynavax Technologies Corporation | $16.43 | 2024 | Heplisav-B |
| Boston Scientific Corporation | $15.57 | 2025 | General - Pain Management |
| Becton, Dickinson and Company | $14.36 | 2024 | Bd Onclarity |
| Insulet Corporation | $14.24 | 2019 | |
| Antares Pharma, INC. | $13.82 | 2024 | Xyosted |
| Vertex Pharmaceuticals Incorporated | $13.63 | 2024 | |
| Amarin Pharma, INC. | $13.30 | 2020 | |
| Merck Sharp & Dohme LLC | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hulbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.